Author:
Raina Rupesh,Sethi Sidharth K.,Filler Guido,Menon Shina,Mittal Aliza,Khooblall Amrit,Khooblall Prajit,Chakraborty Ronith,Adnani Harsha,Vijayvargiya Nina,Teo Sharon,Bhatt Girish,Koh Lee Jin,Mourani Chebl,de Sousa Tavares Marcelo,Alhasan Khalid,Forbes Michael,Dhaliwal Maninder,Raghunathan Veena,Broering Dieter,Sultana Azmeri,Montini Giovanni,Brophy Patrick,McCulloch Mignon,Bunchman Timothy,Yap Hui Kim,Topalglu Rezan,Díaz-González de Ferris Maria
Abstract
Management of acute liver failure (ALF) and acute on chronic liver failure (ACLF) in the pediatric population can be challenging. Kidney manifestations of liver failure, such as hepatorenal syndrome (HRS) and acute kidney injury (AKI), are increasingly prevalent and may portend a poor prognosis. The overall incidence of AKI in children with ALF has not been well-established, partially due to the difficulty of precisely estimating kidney function in these patients. The true incidence of AKI in pediatric patients may still be underestimated due to decreased creatinine production in patients with advanced liver dysfunction and those with critical conditions including shock and cardiovascular compromise with poor kidney perfusion. Current treatment for kidney dysfunction secondary to liver failure include conservative management, intravenous fluids, and kidney replacement therapy (KRT). Despite the paucity of evidence-based recommendations concerning the application of KRT in children with kidney dysfunction in the setting of ALF, expert clinical opinions have been evaluated regarding the optimal modalities and timing of KRT, dialysis/replacement solutions, blood and dialysate flow rates and dialysis dose, and anticoagulation methods.
Subject
Pediatrics, Perinatology and Child Health